| Literature DB >> 28979314 |
Seyed Javad Khoramrouz1, Mostafa Erfani2, Mitra Athari Allaf1.
Abstract
Nuclear medicine imaging has been used to localize infection sites, and efforts have been continued to develop modified infection specific radiopharmaceuticals. In this study gemifloxacin as a broad-spectrum quinolone has been labeled with [99mTc (CO)3 (H2O)3]+ core in order to evaluate its feasibility as an infection imaging agent for in-vivo use. The stability of radioconjugate was checked in human serum at 37 °C and biodistribution was studied in mice. Labeling yield of > 95% was obtained corresponding to a specific activity of 0.14 GBq/μmol. The radioconjugate showed good stability in human serum. Our main achievement was the high accumulation in the infected muscle in mice (T/NT = 2.93 ± 0.3 at 1 h post injection), which may diagnostically be beneficial for differentiate sites of infection from sites of inflammation.Entities:
Keywords: 99mTc-carbonyl; Gemifloxacin; Imaging; Infection; Quinolone
Year: 2017 PMID: 28979314 PMCID: PMC5603869
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Figure 1.preparation and proposed structure of labeled gemifloxacin via carbonyl core
Influence of different amount of gemifloxacin ligand on carbonyl labeling efficiency. Values are expressed as mean ± standard deviation (n = 3
|
|
|
|---|---|
| 0.5 | 3 ± 4.1 |
| 1.0 | 75.3 ± 3.6 |
| 1.5 | 90.4 ± 2.3 |
| 2.0 | 98.2 ± 1.1 |
| 2.5 | 97.8 ± 1.4 |
| 5.0 | 95.1 ± 2.1 |
Figure 2The effect of pH on the labeling yield of 99mTc(CO)3-Gemifloxacin
Figure 3Reversed phase HPLC chromatogram for 99mTc-carbonyl core labeled gemifloxacin using 0.1% trifluoroacetic acid/water (Solvent A) and 0.1% trifluoroacetic acid/acetonitrile (Solvent B) as a mobile phase and the following gradient: 0 min 95% A (5% B), 5 min 95% A (5% B), 25 min 0% A (100% B), 30 min 0% A (100% B), flow = 1 mL/min, λ = 280 nm
Biodistribution of 99mTc(CO)3-Gemifloxacin in mice (%ID/g ± SD, n = 3
|
| |||
|---|---|---|---|
|
|
|
| |
| Blood | 12.15 ± 1.60 | 7.47 ± 1.35 | 2.57 ± 0.18 |
| Heart | 3.16 ± 1.12 | 3.23 ± 0.82 | 0.98 ± 0.15 |
| Lung | 8.51 ± 1.35 | 4.86 ± 0.82 | 1.72 ± 0.31 |
| Stomach Bone | 1.41 ± 0.51 | 1.53 ± 0.21 | 8.00 ± 1.39 |
| Intestine | 2.17 ± 0.64 | 2.11 ± 0.36 | 0.60 ± 0.29 |
| Thyroid | 5.74 ± 1.58 | 6.06 ± 0.72 | 1.37 ± 0.38 |
| Liver | 4.06 ± 1.33 | 3.34 ± 0.35 | 1.19 ± 0.21 |
| Spleen | 14.22 ± 1.38 | 13.18 ± 1.94 | 6.27 ± 0.95 |
| Kidney | 2.78 ± 0.35 | 1.83 ± 0.21 | 1.09 ± 0.28 |
| Non-infected muscle | 13.92 ± 0.47 | 8.59 ± 1.21 | 4.36 ± 0.75 |
|
| 1.38 ± 0.21 | 0.89 ± 0.10 | 0.37 ± 0.04 |
Figure 4Scintigraphy of mice with right thigh muscle staphylococcus aureus infection 1 h post injection of 99mTc(CO)3-Gemifloxacin. (a) hole body scan (b) Infection site (arrow show) after masking of abdominal region